Explore this article's sources with AI
Follow PeptideMethods on Google
What TB-500 actually costs in the US
Zero official US TB-500 prices were found. FDA records show only unfinished bulk powders, and Medicaid's 2026 NADAC file has no match.
Why we wrote this. US TB-500 price pages often mix bulk listings, seller asks and assumed monthly use. This article checks official product and acquisition-cost records instead.
In this article (10 sections)
- TL;DR
- The approval files produced no product to price
- What the NDC records contain
- The Medicaid file had zero matching prices
- Cash and insurance prices remain unresolved
- A compounded quote would be a different category
- Why seller prices are excluded
- There is no defensible monthly cost
- How to check a future price claim
- Medical and regulatory disclaimers
We found zero official US finished-product prices for TB-500. FDA's current Drugs@FDA and Orange Book downloads contained no product under the identity variants checked on 16 November 2026[1][2]. The 2026 Medicaid NADAC file also contained no matching price record[6]. This does not mean TB-500 costs zero dollars. It means the official records did not identify an FDA-approved TB-500 pack with a public US product price.
The National Drug Code directory does contain TB-500 and related thymosin beta-4 records. Every record returned by the two direct ingredient searches was an unfinished bulk-ingredient powder. None was a patient vial, injection or other retail prescription pack. FDA says an NDC listing does not denote approval or establish reimbursement eligibility. Package quantities in grams are not prices.
The identity issue needs care because the grey-market name can refer to an acetylated seven-amino-acid fragment or be used loosely for full-length thymosin beta-4. The TB-500 overview explains that distinction. The United States regulation hub covers the wider approval system. This article asks a narrower question: is there a defined finished product with a comparable official US price? The searched records supplied none.
TL;DR
As of 16 November 2026, we found no FDA-approved TB-500 product and no TB-500 price entry in the 2026 NADAC acquisition-cost file. OpenFDA returned unfinished bulk powders under TB-500 and thymosin beta-4 searches, but no finished product and no price. There is therefore no verified US list price, official cash pack price, standard Medicaid acquisition cost or evidence-based monthly cost to quote. Seller amounts and clinic packages are excluded because they do not establish an approved, comparable finished medicine.
The approval files produced no product to price
Drugs@FDA is FDA's application-based database for approved drug products. Its downloadable archive, updated 13 November 2026, contained zero matches across all twelve files for TB-500, TB 500, TB500, thymosin beta-4, thymosin beta 4, thymosin .beta.-4, thymosin β4, AC-LKKTETQ, LKKTETQ, timbetasin and RGN-259[1]. An exact openFDA Drugs@FDA query for TB-500 also returned 'No matches found.' The stable FDA data-files page is cited because it is the official source for the searched archive.
We checked the Orange Book separately. Its products, patent and exclusivity files returned zero matches for the same eleven identity variants[2]. The Orange Book describes approved drug products and associated application records. A zero result under those names is a bounded database finding. It cannot reveal confidential applications or rule out every possible spelling.
A useful medicine price needs a defined product. At minimum, the record should identify a finished dosage form, strength, package quantity and date. No approved TB-500 record supplied those fields. Full-length thymosin beta-4 research does not create a price for the seven-amino-acid fragment, and an online product does not acquire an official price because its label uses either name.
What the NDC records contain
FDA's NDC directory includes submitted listing data for finished and unfinished drugs, including approved and unapproved products. FDA states that inclusion does not mean the agency verified the information or approved the product[3]. The openFDA data used here was last updated 13 November 2026[4].
The exact active-ingredient query for TB-500 returned eight records. A separate thymosin beta-4 query returned seven[5]. Every returned record had finished set to false, product type BULK INGREDIENT and dosage form POWDER. Some records overlap by naming a thymosin beta-4 fragment as TB-500. We therefore do not add the two query totals and call them fifteen distinct medicines.
The reported packages ranged from 0.1 grams to 5,000 grams and used bottles, bags or bulk containers. Marketing categories included BULK INGREDIENT and BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING. These are labeler-submitted classifications for unfinished material. They do not identify a dispensed injection, patient pack or other finished retail product.
FDA warns that NDC assignment does not denote approval and directory inclusion does not establish Medicare, Medicaid or other payer eligibility[3]. A bulk package quantity is not a medicine price. Dividing a hypothetical ingredient amount by an assumed injection schedule would add an unsupported price, erase the fragment-versus-full-length identity problem and create self-directed dosing guidance.
The Medicaid file had zero matching prices
CMS publishes National Average Drug Acquisition Cost data through Medicaid.gov. NADAC is a weekly reference dataset for retail community pharmacy acquisition costs. The current 2026 CSV available on 16 November was dated 11 November 2026 and contained 1,358,735 rows[6].
We searched every field for TB-500, TB 500, TB500, thymosin beta-4, thymosin beta 4, thymosin .beta.-4, thymosin β4, AC-LKKTETQ, LKKTETQ, timbetasin and RGN-259. Every variant returned zero rows. The inspected file therefore supplied no NADAC per-unit amount, pricing unit, effective date or corresponding generic amount for the identities checked.
NADAC absence has a limited meaning. The current acquisition-cost file supplied no matching price record. It does not prove that no private payer has ever processed an exceptional claim, and NADAC is not a census of cash transactions. It cannot create a price for unfinished powders. The supported conclusion is zero official finished-product prices found, not a zero-dollar price.
Cash and insurance prices remain unresolved
A cash price normally attaches to a named finished product and pack sold through a lawful dispensing route. The approval and pricing files identified no such TB-500 pack. We cannot report an official cash amount, compare pharmacy discounts or calculate a normal retail range. A coupon page or online checkout would not fix the missing product identity.
The same boundary applies to insurance. No approved TB-500 product or NADAC record was found, and the NDC directory says listing does not establish payer eligibility. This does not justify a universal statement about every patient-specific expense under every plan. It does mean there is no standard official reimbursement amount or ordinary finished-product record on which to base a coverage estimate.
General deductibles, copays and Medicaid rules are not TB-500 prices. Applying them would assume that a covered prescription product exists. A reader with a specific claim question needs the exact product, dispensing entity and written payer decision. A name alone is not enough, especially when TB-500 is used for more than one molecular identity.
A compounded quote would be a different category
A patient-specific pharmacy quote, if lawfully offered for an identified preparation, would cover that preparation and service. Professional work, testing, packaging or delivery may affect the total. The quote would not become a national TB-500 list price or prove FDA approval, routine availability or insurance coverage.
The words for human prescription compounding in an NDC record do not establish that a pharmacy may compound TB-500. Eligibility depends on the exact substance, facility and applicable federal and state conditions. A labeler-submitted category does not resolve those questions. Compounded drugs are not FDA approved.
FDA's unapproved-drugs guidance explains why an approval record cannot be replaced by a seller or compounder claim[7]. We found no first-party public quote that qualifies as an official finished-product price. Any individual quote would still require product-identity and regulatory checks before it could be described accurately.
Why seller prices are excluded
Websites advertise vials and powders called TB-500. Those amounts are seller asks, not official medicine prices. Listings differ in claimed molecule, concentration, container size and intended use. Without a common finished product, averaging the amounts would compare unlike items and produce a number with no approved product underneath it.
A seller certificate does not repair the comparison. It may concern one submitted sample without proving the identity, storage history or chain of custody of the item offered to a reader. This is particularly important when the label may refer to the fragment or full-length thymosin beta-4. A research-use statement also does not turn a consumer-facing health product into an approved medicine.
Clinic totals are excluded for the same reason. A package might combine consultation, laboratory work, follow-up and delivery with a claimed product. Without a defined approved pack, the medicine portion cannot be separated into a US list price. A higher amount does not prove quality, while a lower amount does not establish value or lawful supply.
There is no defensible monthly cost
A monthly estimate needs a verified product price and a defined regimen. The official records supplied neither. Multiplying an online amount by an assumed frequency would convert a grey-market listing into dosing guidance. It would also conceal identity, concentration and package differences that make the products incomparable.
The result is narrower: zero official finished-product prices found. That answer preserves the difference between an absent price record and a free product. It could change if FDA approves a defined product or an official pricing dataset adds a matching finished pack.
How to check a future price claim
Start with the exact finished product. Ask for its application number, manufacturer, dosage form, strength and package quantity. Confirm the application in Drugs@FDA and check the Orange Book separately. An NDC alone is insufficient because the directory contains unapproved and unfinished listings.
Then match the same product and pack to the dated price source. A Medicaid acquisition-cost record, manufacturer list price, pharmacy cash quote and insurer payment decision answer different questions. Keep the date and unit attached to the amount. For compounding, identify the pharmacy and exact preparation, and treat the quote as patient-specific rather than a national tariff.
As of 16 November 2026, the official evidence stops before that step. No approved finished product was identified, the direct NDC searches returned only unfinished powders and the 11 November NADAC file contained zero matches. Future price claims should be tested against those product-identity checks rather than an online headline.
Medical and regulatory disclaimers
Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.
Regulatory disclaimer: This page reflects our understanding of the US regulatory status and official price records as of 16 November 2026. Regulations and records change. Verify with FDA, CMS, the relevant state pharmacy regulator and a licensed pharmacy before making any decision. PeptideMethods.com is not a law firm and does not provide legal advice.
Frequently asked
How much does TB-500 cost in the US?
Zero official US finished-product prices were found on 16 November 2026. This means no approved pack with an official price was identified, not that TB-500 costs zero dollars.
Does TB-500 have an FDA list price?
No FDA-approved TB-500 product was identified in Drugs@FDA or the Orange Book, so there is no approved finished pack to which an FDA-linked US product price can be attached.
Why do TB-500 NDC records not provide a price?
The direct ingredient searches returned only unfinished bulk-ingredient powders. FDA says NDC assignment does not denote approval or reimbursement eligibility, and gram quantities are not prices.
Is there a Medicaid or insurance price for TB-500?
The 11 November 2026 NADAC file contained zero matches for the checked identity variants. That means no official NADAC acquisition-cost record was found; it does not decide every possible private claim.
Can seller prices estimate a monthly TB-500 cost?
Not responsibly. Seller listings do not establish a common approved product, and a monthly estimate would add unsupported assumptions about molecular identity, concentration, use frequency and duration.
Sources
- [1]US FDA: Drugs@FDA data files, updated 13 November 2026 and searched on 16 November 2026Tier 1 · primary↩
- [2]US FDA: Orange Book data files, searched on 16 November 2026Tier 1 · primary↩
- [3]US FDA: National Drug Code DirectoryTier 1 · primary↩
- [4]openFDA NDC API: TB-500 listing data, updated 13 November 2026Tier 1 · primary↩
- [5]openFDA NDC API: thymosin beta-4 listing data, updated 13 November 2026Tier 1 · primary↩
- [6]CMS Medicaid: NADAC 2026 CSV dated 11 November 2026Tier 1 · primary↩
- [7]US FDA: Unapproved DrugsTier 1 · primary↩
No revisions yet. First published .